ArticleFrontiers in medicine2026
Tuina therapy for chronic nonspecific low back pain: a randomized clinical trial protocol.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic Non-Specific Low Back Pain (CNLBP) is a prevalent musculoskeletal condition. Tuina therapy and non-steroidal anti-inflammatory drugs (NSAIDs) are two commonly used treatments for CNLBP, both of which have demonstrated some clinical efficacy. However, the effectiveness, safety, and potential opioid-sparing effects of Tuina, a classic complementary and alternative therapy, have yet to be rigorously validated through clinical research. Objective: This study aims to conduct a randomized controlled superiority trial with an open-label design, blinded assessment, and parallel groups to evaluate the effectiveness, safety, and complementary role of Tuina in the treatment of CNLBP. Study design and methods: This is a single-center, randomized controlled, assessor-blind clinical trial. A total of 80 participants aged 18-60 years meeting the diagnostic criteria for CNLBP will be recruited and randomly assigned to either the experimental group (Tuina combined with Loxoprofen Sodium patches) or the control group (Loxoprofen Sodium patches). The Tuina intervention will be administered three times weekly for four consecutive weeks; Loxoprofen Sodium patches will be used as needed. The primary outcome measure is the Visual Analogue Scale (VAS) for pain after 4 weeks of treatment. Secondary outcomes include the Oswestry Disability Index (ODI), 36-Item Short Form Health Survey (SF-36), Beck Depression Inventory-Second Edition (BDI-II), Beck Anxiety Inventory (BAI), Surface Electromyography (sEMG) and musculoskeletal ultrasound (MSK US) parameters, medication usage, and 12-week follow-up data. Statistical analysis will follow the intention-to-treat (ITT) principle, using SPSS 26.0 for between-group comparisons and repeated measures analysis. Discussion: Through a rigorous randomized controlled design incorporating both physiological and morphological objective indicators, this study aims to provide high-level evidence regarding the analgesic efficacy, safety, and potential for drug dose reduction of Tuina in treating CNLBP. It also seeks to offer clinical evidence and practical references for the application of Tuina in the rehabilitation of musculoskeletal disorders. Clinical trial registration: https://itmctr.ccebtcm.org.cn/mgt/project/user/user-project-view/4621255a-332d-4ba4-b09b-e9412ba06d0b, Identifier (ITMCTR2026000745).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.